Transgene

TNG

FR0005175080

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 05:55:05 2024-04-24 am EDT			5-day change	1st Jan Change
1.32 ^EUR	-0.15%		-10.81%	-3.65%

Apr. 10	Transgene: presents vaccine results at AACR	CF
Mar. 28	Transgene CFO Steps Down; Successor Assumes Office	MT

Transgene: Half-Year Report on the Transgene Liquidity Contract with Kepler Cheuvreux

January 14, 2020 at 12:01 pm EST

Regulatory News:

Under the liquidity contract between Transgene (Paris:TNG) and Kepler Cheuvreux, on December 31, 2019, the resources provided for market making activities consisted of:

- 164,183 Transgene Shares
- € 246,158.00

In light of the transfer of management of the liquidity program to Natixis Oddo BHF SCA with effect as of January 2, 2020, market making activities were suspended on December 23, 2019.

For information, on June 30, 2019, the resources provided for market making activities consisted of:

- 89 677 Transgene Shares
- € 372,551.76

View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005567/en/

Latest news about Transgene

Transgene: presents vaccine results at AACR	Apr. 10	CF
Transgene CFO Steps Down; Successor Assumes Office	Mar. 28	MT
Transcript : Transgene SA, 2023 Earnings Call, Mar 27, 2024	Mar. 27
Transgene SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Transgene SA Announces Chief Financial Officer Changes	Mar. 27	CI
Transgene SA Promotes Christelle Schwoerer to Chief Human Resources Officer, Effective from April 1, 2024, and She Also Joins the Executive Committee	Mar. 27	CI
Fractyl Health Reports 'Promising' Preclinical Findings From Rejuva Platform; Shares Fall	Mar. 12	MT
Transgene, NEC Corporation and BostonGene Corporation Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	Mar. 05	CI
Transgene Appoints Chief Business Officer	Jan. 23	MT
Transgene Appoints James Wentworth as Chief Business Officer and Member of Executive Management Team	Jan. 22	CI
Transgene: new CFO, share price rises	Dec. 06	CF
Biotech Group Transgene Names CFO	Dec. 06	MT
UniQure Says US FDA Clears Investigational New Drug Application for Fabry Disease Candidate	Nov. 29	MT
Transgene and BioInvent International AB Announces First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA	23-10-10	CI
Transcript : Transgene SA, H1 2023 Earnings Call, Sep 20, 2023	23-09-20
Transgene SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
Transgene Obtains $15 Million from Sale of Minority Stake in Chinese Biopharmaceutical Group	23-07-18	MT
4D Molecular Reports Positive Interim Data in Phase 1/2 AEROW Clinical Trial of 4D-710; Shares Jump	23-06-07	MT
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023	23-06-06	CI
BioInvent Ready for Combination Studies with BT-001	23-06-05	CI
Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023	23-06-05	CI
Global markets live: Nvidia, Snowflake, Best Buy, Verizon, Microsoft...	23-05-25
Transgene, BioInvent's Oncolytic Virus Shows Antitumor Potential in Early-stage Study	23-05-25	MT
Voyager Therapeutics Says Preclinical Studies Show Ability of Capsids to Produce Desirable Features in Several Brain Areas	23-05-18	MT
Oxford Nanopore, PathoQuest Partner to Develop New Testing Service for Biopharma Sector	23-05-12	MT

Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 5 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon and China.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Transgene

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.322 EUR

Average target price

3.5 EUR

Spread / Average Target

+164.75%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TRANSGENE	-3.65%	142M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+2.82%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-7.42%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs

Transgene

Equities

TNG

FR0005175080

Biotechnology & Medical Research

Transgene: Half-Year Report on the Transgene Liquidity Contract with Kepler Cheuvreux

Latest news about Transgene

Chart Transgene

Company Profile

Income Statement Evolution

Ratings for Transgene

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs